Database Query Results : , , HMG-CoA

HMG-CoA, Mevalonate pathway: Click to Expand ⟱
Source:
Type:
HMG‐CoA (3‐hydroxy-3‐methylglutaryl‐coenzyme A) 
Mevalonate pathway → Primary pathway entry
-HMG-CoA reductase (HMGCR) → rate-limiting node / druggable target
-Downstream nodes: prenylation, cholesterol synthesis, CoQ
HMG‐CoA is not a single enzyme but rather a key metabolic intermediate in the mevalonate pathway that underlies cholesterol and isoprenoid biosynthesis.
– HMG‐CoA is a pivotal intermediate formed from acetyl‐CoA (via the enzyme HMG‐CoA synthase) that subsequently undergoes reduction (via HMG‐CoA reductase) to produce mevalonate.
– The mevalonate pathway supplies cholesterol and other isoprenoids, which are essential for membrane biogenesis, protein prenylation, and other cellular functions that support cell proliferation and survival.
– The availability of HMG‐CoA and subsequent metabolites has implications for modifying cell signaling pathways, including those involved in the regulation of cell growth, differentiation, and apoptosis.
– Markers of an activated mevalonate pathway (such as increased expression of HMG‐CoA synthase or HMG‐CoA reductase) have been associated with aggressive tumor phenotypes in several cancer types, including breast, prostate, and liver cancers.
Scientific Papers found: Click to Expand⟱
5454- ATV,    Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility
- Review, BC, NA
HMG-CoA↓, HMGCR↓, TumCP↓, RadioS↑, CD44↓, P53↑,
5452- ATV,    Mevalonate pathway in pancreatic ductal adenocarcinoma: mechanisms driving metabolic and cellular plasticity
- Review, Var, NA
ChemoSen↑, HMG-CoA↓, EMT↓, Ferroptosis↑, Hif1a↓,
5451- ATV,    In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, GBM, U87MG - in-vitro, GBM, A172
TumAuto↑, CSCs↓, HMG-CoA↓, TumCP↓, tumCV↓, TumCCA↑, TumCG↓, HMGCR↓,
5447- ATV,    The Mevalonate Pathway, a Metabolic Target in Cancer Therapy
- Review, Var, NA
Risk↓, Dose↑, ChemoSen↑, chemoP↑, HMG-CoA↓, EMT↓, CSCs↓, HH↝, YAP/TEAD↝,
5446- ATV,    Targeting the Mevalonate Pathway in Cancer
- Review, Var, NA
EMT↓, HMG-CoA↓,
5445- ATV,    Atorvastatin
- NA, Nor, NA
*cardioP↑, *LDL↓, HMG-CoA↓, Half-Life↝, BioAv↓, Dose↝,
5449- ATV,    Pleiotropic effects of statins: A focus on cancer
- NA, Var, NA
lipid-P↓, TumCG↓, Apoptosis↑, ChemoSen↑, RAS↓, HMG-CoA↓, HMGCR↓, LDL↓, toxicity↓, Risk↓, P21↑, HDAC↓, Bcl-2↓, BAX↑, BIM↑, Casp↑, cl‑PARP↑, MMP↓, ROS↑, angioG↓, TumMeta↓, PTEN↑, eff↑, OS↑, Remission↑,
4982- ATV,    Inhibiting the mevalonate pathway with atorvastatin alters gut microbiota and has potential as an anti-cancer treatment for ovarian cancer
- in-vivo, Ovarian, NA
HMG-CoA↓, GutMicro↑,
4981- ATV,    Crosstalk between Statins and Cancer Prevention and Therapy: An Update
Apoptosis↑, selectivity↑, eff↑, HMG-CoA↓, *cardioP↑, OS↑, IL1β↓, IL6↓, IL8↓, TNF-α↓, TumAuto↑, Histones↝, ac‑H3↑, ac‑H4↑, HDAC↓,
4980- ATV,    A review of effects of atorvastatin in cancer therapy
- Review, Var, NA
HMG-CoA↓, TumCP↓, TumCMig↓,
4985- ATV,  Dipy,    Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell Lines
- in-vivo, Melanoma, SK-MEL-28 - in-vitro, BC, MDA-MB-435
HMG-CoA↓, SREBP2↓, eff↑, HMGCR⇅, ChemoSen↑,
4986- ATV,  Dipy,    The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer
- Review, Var, NA
HMG-CoA↓, AntiAg↑, eff↑, Apoptosis↑, selectivity↑, *toxicity↓, TumCG↓, PDE4↓, other↑,
4984- Dipy,  ATV,    Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop
- in-vitro, AML, NA
eff↑, Apoptosis↑, selectivity↑, TumCG↓, HMG-CoA↓, HMGCR↑,
4983- Dipy,  ATV,    Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one
- Review, Var, NA
HMG-CoA↓, AntiTum↓, eff↑,
1575- statins,  Citrate,    Inhibition of Lung Cancer Growth: ATP Citrate Lyase Knockdown and Statin Treatment Leads to Dual Blockade of Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol-3-Kinase (PI3K)/AKT Pathways
- in-vitro, NSCLC, A549
eff↑, HMG-CoA↓, eff↑, AntiTum↑, EGFR↓, eff↑, ROS↑, EMT↓, E-cadherin↑, MUC1↑, p‑ACLY↓, p‑Akt↓, eff↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 15

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   lipid-P↓, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

p‑ACLY↓, 1,   Histones↝, 1,   HMG-CoA↓, 15,   LDL↓, 1,   SREBP2↓, 1,  

Cell Death ⓘ

p‑Akt↓, 1,   Apoptosis↑, 4,   BAX↑, 1,   Bcl-2↓, 1,   BIM↑, 1,   Casp↑, 1,   Ferroptosis↑, 1,   YAP/TEAD↝, 1,  

Transcription & Epigenetics ⓘ

ac‑H3↑, 1,   ac‑H4↑, 1,   other↑, 1,   tumCV↓, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 2,  

DNA Damage & Repair ⓘ

P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   CSCs↓, 2,   EMT↓, 4,   HDAC↓, 2,   HH↝, 1,   HMGCR↓, 3,   HMGCR↑, 1,   HMGCR⇅, 1,   PTEN↑, 1,   RAS↓, 1,   TumCG↓, 4,  

Migration ⓘ

AntiAg↑, 1,   E-cadherin↑, 1,   MUC1↑, 1,   TumCMig↓, 1,   TumCP↓, 3,   TumMeta↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EGFR↓, 1,   Hif1a↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   ChemoSen↑, 4,   Dose↑, 1,   Dose↝, 1,   eff↑, 10,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiTum↓, 1,   AntiTum↑, 1,   chemoP↑, 1,   OS↑, 2,   PDE4↓, 1,   Remission↑, 1,   Risk↓, 2,   toxicity↓, 1,  
Total Targets: 69

Pathway results for Effect on Normal Cells:


Core Metabolism/Glycolysis ⓘ

LDL↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 2,   toxicity↓, 1,  
Total Targets: 3

Scientific Paper Hit Count for: HMG-CoA, Mevalonate pathway
14 Atorvastatin
4 Dipyridamole
1 statins
1 Citric Acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1143  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page